Rapt Therapeutics Inc. (US75382E1091)
XSTU 
Summary
RAPT Therapeutics: Strong Promise In Immunology, Looking Like An Opportunity At These Prices
RAPT Therapeutics is upgraded to a 'Buy' due to promising pipeline progress and attractive valuation after a significant share price decline. Ozureprubart, RAPT's lead candidate, showed favorable phase 2 data in chronic spontaneous urticaria, with potential for less frequent dosing than competitors. RAPT's strong cash position, bolstered by a $250 million offering, provides operational runway, but future cash burn for pivotal trials remains a risk.
Wall Street Analysts Think Rapt Therapeutics (RAPT) Could Surge 101.02%: Read This Before Placing a Bet
The consensus price target hints at a 101% upside potential for Rapt Therapeutics (RAPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Rapt Therapeutics (RAPT)'s Technical Outlook is Bright After Key Golden Cross
After reaching an important support level, Rapt Therapeutics (RAPT) could be a good stock pick from a technical perspective. RAPT recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
Rapt Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Brian Russell Wong CEO | XSTU Exchange | US75382E2081 ISIN |
| US Country | 67 Employees | - Last Dividend | 17 Jun 2025 Last Split | 31 Oct 2019 IPO Date |
Overview
RAPT Therapeutics, Inc. is a pioneering clinical-stage immunology-based biopharmaceutical company that is at the forefront of developing oral small molecule therapies. With a focus on addressing the unmet needs of patients battling oncology and inflammatory diseases within the United States, RAPT Therapeutics is dedicated to advancing the field of medicine through its innovative research and development efforts. Initially established as FLX Bio, Inc., the company underwent a strategic rebranding to RAPT Therapeutics, Inc. in May 2019, signaling its deepened commitment to exploring therapeutic possibilities and enhancing patient care. Founded in 2015 and having its headquarters in South San Francisco, California, RAPT Therapeutics operates under the umbrella of Bristol-Myers Squibb Company, marking its stature as a noteworthy subsidiary within the pharmaceutical industry.
Products and Services
-
Zelnecirnon (RPT193)
As RAPT Therapeutics' leading inflammation drug candidate, zelnecirnon, scientifically referred to as RPT193, represents a significant advancement in the treatment of inflammatory diseases. This innovative oral small molecule therapy functions as a C-C motif chemokine receptor 4 (CCR4) antagonist. Its mechanism of action is specifically designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues, thereby offering a novel approach to mitigating the effects of chronic inflammatory conditions. The drug's focus on targeting the root causes of inflammation at the cellular level underscores RAPT Therapeutics' commitment to addressing complex immunological challenges through targeted therapy.
-
Tivumecirnon (FLX475)
Marking its prominence in RAPT Therapeutics' oncology portfolio, tivumecirnon, known as FLX475, is the company's premier oncology drug candidate. This oral small molecule therapy shares its CCR4 antagonist classification with its counterpart in the inflammation domain, zelnecirnon, but is uniquely tailored for combating cancer. Tivumecirnon is currently undergoing a Phase 1/2 clinical trial, where its efficacy as both a monotherapy and in combination with pembrolizumab is under investigation in patients with advanced cancer. This comprehensive clinical trial aims to validate tivumecirnon's potential to revolutionize cancer treatment through its targeted, minimally invasive approach, highlighting RAPT Therapeutics' dedication to pioneering in the field of cancer therapy.
